Post-CA Neuroprotection With Magnesium

Part of paid clinical trials in New York, New York.

Sponsor
NYU Langone Health
Study ID
NCT06455514
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Cardiac Arrest
  • Return of Spontaneous Circulation

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Magnesium Sulfate — DRUG
    4 g of magnesium sulfate intravenously within 2 hours of Return of Spontaneous Circulation (ROSC), followed by a continuous drip (16 g) over 24 hours
  • Saline — DRUG
    Control subjects will receive an equivalent volume of normal saline intravenously.

Study Details

The purpose of this pilot interventional study is to collect preliminary data on administering magnesium sulfate as a neuroprotective medication in patients who achieved Return of Spontaneous Circulation (ROSC) following Cardiac Arrest (CA). The primary aims are to assess the feasibility and safety of administering magnesium and measure serum markers of neuronal injury at prespecified time points in the post-cardiac arrest period. Because this is a pilot study with a limited sample size, the primary objective is to evaluate the precision and stability of the collected measures to inform the design and formal analysis in a larger trial.

Key Dates

Start date
Mar 25, 2025
Status verified
Apr 2026
Primary completion
Mar 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
178 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Magnesium Sulfate
    Treatment of initial magnesium sulfate bolus followed by a continuous drip.
  • Placebo Comparator: Saline solution
    Treatment of equivalent volume of normal saline.

Primary Outcome Measure

Proportion of cases where successful randomization occurred [ Time Frame: Through study completion, an average of 90 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
NYU Langone HealthNew YorkNew York10016-

Find similar trials in New York, NY

By research site
NYU Langone Health· New York, NY

Related Studies